Track Medicus Pharma Ltd. Common Stock's EBIT ($-28M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2026
Trailing 12 months ending Sep 30, 2026
Medicus Pharma Ltd. Common Stock (MDCX) currently reports a EBIT of $-28M as of September 2026. That compares with $-29M in the prior-year period — up 3.6% year over year. That is below the Healthcare sector average of $1.1T. Use the charts on this page to explore Medicus Pharma Ltd. Common Stock's EBIT history and peer comparisons.
Medicus Pharma Ltd. Common Stock's EBIT increased from $-29M to $-28M — a 3.6% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Medicus Pharma Ltd. Common Stock's EBIT of $-28M is lower than the Healthcare sector average of $1.1T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
Medicus Pharma Ltd. Common Stock reported $-28M in EBIT as of September 2026. That compares with $-29M in the prior-year period — up 3.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current EBIT of $-28M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $1.1T. From there, open related valuation or income-statement pages for Medicus Pharma Ltd. Common Stock, and consider following MDCX for alerts when major investors trade the stock.